Lowering the Cost of Genomic Testing: Technology and Economic Trends

Introduction
Genomic testing has transitioned from a research luxury to a cornerstone of precision medicine, thanks largely to falling sequencing costs and smarter analytic strategies. Innovations like low-coverage whole-genome sequencing (LC-WGS) make it possible to deliver rich genetic insights without the traditionally high price tag (https://www.nature.com/articles/s41591-022-01767-6). 

From Costly to Convenient: How Sequencing Has Changed

Early whole-genome sequencing required high depth and expensive infrastructure, keeping it out of reach for widespread clinical use. Today, scalable approaches such as LC-WGS paired with statistical imputation enable affordable genome-wide analysis suitable for large populations (https://www.nature.com/articles/s41591-022-01767-6). 

Studies show that even with lower coverage, genomic data can accurately capture common genetic variants across the genome, enabling reliable calculation of polygenic risk scores (PRS) without high costs (https://www.nature.com/articles/s41591-022-01767-6). 

The Economic Case for Broader Genomic Screens

As the cost per genome drops, health systems can justify the adoption of expanded genomic profiling for preventive programs, especially when early detection leads to reduced downstream healthcare expenditure (https://www.tandfonline.com/doi/full/10.1080/14737159.2023.2176753). 

Integrating genomic risk scores into preventive care could potentially:

• Reduce long-term treatment costs
• Improve population health outcomes through earlier intervention
• Support more personalized medical decisions

Where Genomic Medicine Is Going

The combination of faster sequencing, advanced analytics, and cheaper technology platforms makes genomic healthcare more attainable than ever. As adoption grows, economies of scale and continuous innovation are likely to further reduce costs and expand use cases across disease areas.